AMSTERDAM, NETHERLANDS – 15th September 2022 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that the Company was awarded ‘Best ADC Platform Technology’ at the World ADC Conference 2022. Read more…
Kyowa Kirin expands the license agreement with one new ADC to a total of three ADC programs Kyowa Kirin also exercises exclusive target option for development and commercialization against an undisclosed ADC targetad technologies to develop up to three next generation conjugates Decisions driven by highly competitive preclinical therapeutic index demonstrated by Kyowa Kirin’s lead […]
Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies Genmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive worldwide development and commercialization of resulting therapies Synaffix to receive an upfront payment of USD $4.5 million with a total deal value of up to USD $415 million plus […]
